肝病肌肉减少症发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2022.02.038

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 301-304.doi: 10.3969/j.issn.1672-5069.2022.02.038

• 综述 • 上一篇

肝病肌肉减少症发病机制研究进展^*

蔺宁, 孔明综述, 段钟平审校

100069 北京市首都医科大学附属北京佑安医院肝病中心四科

收稿日期:2021-06-20 出版日期:2022-03-10 发布日期:2022-03-15
通讯作者: 段钟平,E-mail:duan@ccmu.edu.cn
作者简介:蔺宁,女,23岁,硕士研究生
基金资助:
*国家重点研发计划资助项目(编号:2017YFA0103000);北京市医院管理局临床医学发展专项经费资助项目(编号:ZYLX201806)

Pathogenesis of sarcopenia in liver diseases

Lin Ning, Kong Ming, Duan Zhongping

Fourth Centre for Liver Disease Study, Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2021-06-20 Online:2022-03-10 Published:2022-03-15

摘要/Abstract

摘要： 目的肌肉减少症是指全身性肌肉质量降低和力量减退,机体生理功能障碍,并导致生活质量下降,甚至死亡的综合征,简称肌少症。肌少症可影响高达70%晚期肝病患者,与不良结局和预后相关。但目前大多数治疗以营养、运动等干预为主,尚缺乏疗效肯定的针对发病机制的治疗药物。本文总结了慢性肝病肌肉减少症的发病机制,以便确定治疗干预的靶点,改善临床预后。

关键词: 慢性肝病, 肌肉减少症, 发病机制

Abstract: Objective Sarcopenia is defined as loss of systemic skeletal muscle mass and functions. It may affect the physiological functions and leads to the declined quality of life, and even death. Sarcopenia occurs in up to 70% of patients with advanced liver diseases, which is associated with untoward clinical outcomes and poor prognosis. At present, most treatments are based on nutrition and exercise, however, there is still a lack of effective targeted molecular therapy. This review summarizes the pathogenesis of sarcopenia in liver diseases, in order to identify potential biomarkers for treatment and improve the clinical prognosis.

Key words: Liver diseases, Sarcopenia, Pathogenesis

蔺宁, 孔明, 段钟平. 肝病肌肉减少症发病机制研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 301-304.

Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases[J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.

参考文献

[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world.J Hepatol,2019,70(1):151-171.
[2] Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.Aliment Pharmacol Ther,2020,51(1):64-77.
[3] Meyer F, Bannert K, Wiese M,et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci,2020, 21(15):5357.
[4] Kang SH, Jeong WK, Baik SK,et al. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle,2018,9(5):860-870.
[5] Ooi PH, Gilmour SM, Yap J,et al. Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review. Clin Nutr ESPEN,2018,28:41-51.
[6] Les I, Doval E, García-Martínez R,et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.Am J Gastroenterol,2011,106(6):1081-1088.
[7] Bojko M. Causes of sarcopenia in liver cirrhosis.Clin Liver Dis (Hoboken),2019, 14(5):167-170.
[8] Khoshnood A, Nasiri Toosi M, Faravash MJ,et al. A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis. Hepat Mon,2013,13(2):e6181.
[9] Ibebunjo C, Eash JK, Li C, et al. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement.Am J Physiol Endocrinol Metab,2011,300(2):E327-340.
[10] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.J Hepatol,2016,65(5):906-913.
[11] Qiu J, Thapaliya S, Runkana A,et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism.Proc Natl Acad Sci U S A,2013,110(45):18162-18167.
[12] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease.J Hepatol,2016,65(6):1232-1244.
[13] Qiu J, Tsien C, Thapalaya S, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis.Am J Physiol Endocrinol Metab,2012,303(8):E983-E993.
[14] Mcdaniel J, Davuluri G, Hill EA, et al. Hyperammonemia results in reduced muscle function independent ofmuscle mass.Am J Physiol Gastrointest Liver Physiol, 2016,310(3):G163-G170.
[15] Campos F, Abrigo J, Aguirre F, et al. Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin-proteasome system and oxidative stress. Pflugers Arch,2018,470(10):1503-1519.
[16] 肖慧娟,张明,齐玉梅,等.肌肉减少症与慢性肝脏病的研究进展.中华肝脏病杂志, 2019,27(7):563-566.
[17] Da Rocha AL, Pinto AP, Morais GP, et al. Moderate, but not excessive, training attenuates autophagy machinery in metabolic tissues.Int J Mol Sci,2020,21(22):8416.
[18] Mangner N, Linke A, Oberbach A, et al. Exercise training prevents TNF-αinduced loss of force in the diaphragm of mice.PLoS One,2013,8(1):e52274.
[19] Ticinesi A, Lauretani F, Tana C, et al. Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis.Exerc Immunol Rev,2019,25:84-95.
[20] Yan J, Herzog JW, Tsang K, et al. Gut microbiota induce IGF-1 and promote bone formation and growth.Proc Natl Acad Sci USA,2016,113(47):E7554-E7563.
[21] Dasarathy J, Mccullough AJ, Dasarathy S. Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res,2017,41(8):1419-1431.
[22] Bonet-Ponce L, Saez-Atienzar S, Da CC, et al. On the mechanism underlying ethanol-induced mitochondrial dynamic disruption and autophagy response. Biochim Biophys Acta,2015,1852(7):1400-1409.
[23] NammiS, Roufogalis BD. Light-to-moderate ethanol feeding augments AMPK-alpha phosphorylation and attenuates SREBP-1 expression in the liver of rats.J Pharm Pharm Sci,2013,16(2):342-351.
[24] Hong-Brown LQ, Brown CR, Kazi AA, et al. Rag GTPases and AMPK/TSC2/Rheb mediate the differential regulation of mTORC1 signaling in response to alcohol and leucine.Am J Physiol Cell Physiol,2012,302(10):C1557-C1565.
[25] Chiang JY.Bileacid metabolism and signaling.Compr Physiol,2013,3(3):1191-1212.
[26] Abrigo J, Gonzalez F, Aguirre F, et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor.J Cell Physiol,2021,236(1):260-272.
[27] Tanaka M, Okada H, Hashimoto Y, et al. Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography.Liver Int,2020,40(1):120-130.
[28] Hsieh YC, Joo SK, Koo BK, et al. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int,2021,41(3):494-504.
[29] Conte M, Armani A, Conte G, et al. Muscle-specificperilipin 2 down-regulation affects lipid metabolism and induces myofiber hypertrophy.J Cachexia Sarcop Muscl,2019,10(1):95-110.
[30] Pravisani R, Soyama A, Isola M, et al. Chronological changes in skeletal muscle mass following living-donor liver transplantation: An analysis of the predictive factors for long-term post-transplant low muscularity.Clin Transplant,2019,33(4):e13495.
[31] Kallwitz ER.Sarcopenia and liver transplant: The relevance of too little muscle mass.World J Gastroenterol,2015,21(39):10982-10993.

肝病肌肉减少症发病机制研究进展^*

Pathogenesis of sarcopenia in liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	毕再鸿, 韩白乙拉, 王炳元. 治疗慢性肝病的新药:辛伐他汀^*[J]. 实用肝脏病杂志, 2021, 24(4): 603-606.
[2]	宋叶雨(综述), 范建高(审校). 少肌性肥胖合并脂肪性肝病的诊断与治疗[J]. 实用肝脏病杂志, 2021, 24(1): 149-152.
[3]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[4]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[5]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[6]	唐承薇. 慢性肝病与血小板减少：临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[7]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[8]	胡虎兰综述, 朱梦飞, 施军平审校. 慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展^*[J]. 实用肝脏病杂志, 2019, 22(1): 149-152.
[9]	夏庚综述, 祁飞, 杨晋辉审校. 自身免疫性肝炎诱发因素研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 983-986.
[10]	崔瑞冰, 阎明. 腹水原因解析[J]. 实用肝脏病杂志, 2018, 21(5): 657-660.
[11]	李越, 丁惠国. 乳糜性腹水诊治现状^*[J]. 实用肝脏病杂志, 2018, 21(5): 665-668.
[12]	曾民德. 非酒精性脂肪性肝病脂毒性多臂表型研究进展[J]. 实用肝脏病杂志, 2018, 21(2): 153-156.
[13]	池肇春. 非酒精性脂肪性肝炎肝硬化发病机制研究进展与展望[J]. 实用肝脏病杂志, 2018, 21(2): 166-169.
[14]	王艳欣综述, 于红卫, 朱跃科审校. 慢性肝病的营养评估与治疗*[J]. 实用肝脏病杂志, 2018, 21(2): 317-320.
[15]	吴丽蒙综述，赵久法审校. Treg和Th17细胞在慢加急性乙型肝炎肝衰竭发病机制中的作用研究进展[J]. 实用肝脏病杂志, 2017, 20(5): 639-642.